Evidence-Based Series 12-11

A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)

Patient Safety Issues: Key Components of Chemotherapy Labelling


Report Date: August 6, 2009

An assessment conducted in January 2017 deferred the review of Evidence-based Series (EBS) 12-11, which means that the document remains current until it is assessed again next year. The PEBC has a formal and standardized process to ensure the currency of each document (PEBC Assessment & Review Protocol).

The full Evidence-based Series 12-11 is comprised of 3 sections and is available on the CCO website on the PEBC Systemic Treatment page.

Section 1: Recommendations
Section 2: Evidentiary Base
Section 3: EBS Development Methods and External Review Process

For information about the PEBC and the most current version of all reports, please visit the CCO website at http://www.cancercare.on.ca/ or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822 Fax: 905-526-6775 E-mail: ccopgi@mcmaster.ca


Evidence-Based Series 12-11: Section 1

Patient Safety Issues: Key Components of Chemotherapy Labelling: Guideline Recommendations


A Quality Initiative of the Chemotherapy Labelling Panel
Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)

Report Date: August 6, 2009

QUESTION
What are the necessary components and formatting of a chemotherapy label to maximize safe delivery and minimize errors? Chemotherapy labels associated with the delivery of a dose of intravenous chemotherapy are of particular interest.

INTENDED USERS
The intended users of this guidance document are any health care professionals who prescribe, prepare, or administer intravenous chemotherapy, including medical oncologists, pharmacists, pharmacy technicians, and oncology nurses, as well as designers of prescription label software, patient safety directors in organizations, administrators of hospitals, and community access care organizations.

RECOMMENDATIONS
The following recommendations are based on the expert opinion of the Chemotherapy Labelling Panel but informed by the currently available evidence (see Section 2). The evidentiary base is composed of three guidelines developed by expert groups, one systematic review, and 13 studies of varying design and sample size. These recommendations apply to the production of intravenous chemotherapy labels in a cancer setting. Although the production of labels for investigational cancer drugs was not specifically examined, the same principles apply for all intravenous chemotherapy labels. Examples of labels using these recommendations are included at the end of this section.
1. General Components for Medication Labels

The following are general components of an optimal drug label for injectable dosage forms.

(a) Identifying Information
- Patient’s name (first name, middle name or initial, and last name OR last name, first name, and middle name or initial such that it is consistent with the rest of the patient record) and unique identifier
- Drug name
- Amount of drug per container
- In those circumstances in which overfill is required, the overfill volume (in mL) should be printed on the label separately from the dose information
- If a product contains two or more active ingredients, they should all appear in the generic name field

(b) Drug Information
- Route of administration
- Amount of drug per dose (when the container holds more than one dose, e.g., multiple doses administered intermittently over a 24-hour time period)

(c) Administration Information
- Volume of fluid to be administered
- Duration of infusion
- Rate of administration expressed in mL/hour or as a duration in minutes in the case of medications given by IV push. There is a need to standardize pump technology within an institution or at least to use pumps with a common format. The use of pumps programmed in mL/hour is strongly recommended over the use of pumps programmed in mL/24 hour.
- Supplemental administration instructions (e.g., starting and completion dates/times, prohibitions about when medications are to be administered with respect to other medications, warnings about route of administration, handling and storage conditions)
- Numbering of the medication containers, when the drug is to be administered sequentially (e.g., bag 1 of 3)
- Relevant auxiliary information should be included on auxiliary labels. Examples of auxiliary labels include “AVOID EXTRAVASATION” and “FOR INTRAVENOUS USE ONLY - FATAL IF GIVEN BY OTHER ROUTES”

(d) General Formatting
- Allow for text wrap and continuation of information on another label. This is intended to allow for long names and enough space to ensure readability as well as eliminating the need to add in additional hand-written information.
- Use white labels: better visualization of text and bar codes (if used). Use black for bar codes.
- If a different colour label is required to draw attention to a specific class of high-alert drug, use yellow labels.
2. **General Principles for Label Preparation**  
The following are general formatting principles to be considered when preparing a chemotherapy drug label for injectable dosage forms.

**(a) Drug Name**  
The following practices are recommended:  
- Use the complete generic drug name rather than an abbreviated version.  
  - cisplatin not CDDP  
- Use lower case or mixed case lettering for generic drug names as appropriate  
  - Use TALL man lettering to differentiate between look alike/sound alike drug names (examples can be found at [http://www.ismp.org/tools/tallmanletters.pdf](http://www.ismp.org/tools/tallmanletters.pdf))  
  - CISplatin to differentiate it from CARBoplatin  
- List the brand name using uppercase letters.  
  - HERCEPTIN

**(b) Abbreviations and Dose Designations**  
The recommended practice is to follow Institute for Safe Medication Practices (ISMP) guidelines for abbreviations and dose expressions (examples are provided in Section 2, Table 6) and United States Pharmacopeia (USP) standards for dosage units and standard units for weight and measures (examples are provided in Section 2, Table 7). Alternative abbreviations and dose expressions should be avoided.

**(c) Font, Font Size, and Formatting**  
It is recommended that:  
- Patient name, generic drug name and patient specific dose are bolded.  
- 12-point Arial, Verdana or an equivalent proportionally spaced font is used for all text and numbers.  
  - Jane A. Smith not Jane A. Smith  
- When drug name, strength, dosage form, and dosage units appear together, provide a space between them  
  - propranolol 20 mg not propranolol20 mg  
- Laser printers that support all label formatting expectations be used.

**(d) Order of Information**  
It is recommended that label information should be presented in the following order: generic name, brand name, patient dose, dosage units, and route of administration.  
- **ondansetron** (ZOFRAN) **4 mg IV Push**  
  - Dose = 4 mg = 2 mL  
  - (2mg per mL)*  
  *include this information only if needed by practitioners (e.g., to program infusion pump)  
- The order of information on the label should match the user’s workflow; that is the order in which information is programmed into the pump. This will vary depending on the type of pump used in an institution.

**(e) Technology**  
- While more evidence is required, the use of bar coding may be considered for use.  
- The use of computerized physician order entry (CPOE) is recommended.
KEY EVIDENCE

- Guideline documents (1-3) provided a framework to identify domains that ought to be considered in an optimal label.
- Label generation should be guided by the overarching rule that medication labels not contain any unnecessary information (4).
- Communication of orders for infusions should be standardized such that “mL per hour” is used rather than “mL per 24 hour” (4).
- ISMP Canada (5) and ISMP United States [US] (6) provide sets of abbreviations, symbols and dose designations that should not be used, which the authors of this document endorse. Please see Tables 6 and 7 in Section 2 for examples.
- TALL man lettering has consistently been shown to reduce drug name identification errors (7-10).
- Larger font size and font weight results in fewer reading errors (11) and better knowledge acquisition (12).
- Proportionally spaced fonts result in better reading speed and accuracy (11).
- There are beginning studies on bar coding indicating that medication administration errors may be reduced with the use of this technology (13, 14). More research is needed before a recommendation regarding this technology can be made.
- CPOE has been demonstrated to reduce medication errors (15-19).
- There is limited evidence that laser printers are preferred over dot-matrix printers (20).

Examples of Labels using the Recommendations in this Guidance Document

The following examples are for illustrative purposes and do not account for overfill volumes which may require consideration.

Example 1 - Intravenous Infusion

<table>
<thead>
<tr>
<th>Smith, John A.</th>
<th>20000133</th>
</tr>
</thead>
<tbody>
<tr>
<td>irinotecan hcl 320 mg/16 mL IV (20 mg/mL)</td>
<td>Drug Name/Amount of Drug/Route of Administration</td>
</tr>
<tr>
<td>solution: D5W, volume: 500 mL</td>
<td>Diluent/Amount of Diluent</td>
</tr>
<tr>
<td>total volume: 516 mL</td>
<td>Volume of Fluid to be Administered</td>
</tr>
<tr>
<td>rate: 344 mL/hour</td>
<td>Rate of Administration</td>
</tr>
<tr>
<td>Infuse IV over 90 minutes; run concurrently with leucovorin calcium.</td>
<td>Administration Instructions</td>
</tr>
<tr>
<td>date: 12-Jun-2009</td>
<td>Date</td>
</tr>
</tbody>
</table>
Example 2 - Intravenous Infusion

Smith, John A. 20000133
leucovorin calcium 360 mg/36 mL IV (10 mg/mL)
solution: D5W volume: 250 mL
total volume: 286 mL
rate: 191 mL/hour

Infuse IV over 90 minutes; run concurrently with irinotecan.
date:12-Jun-2009

Example 3 - Continuous Intravenous Infusion

Smith, John A. 20000133
fluorouracil 4350 mg/87 mL CIV (50 mg/mL)
solution: D5W volume: 146 mL
total volume: 233 mL
rate: 5 mL/hour

IV continuous infusion over 46 hours.
*** INSERT INFUSOR REFERENCE NUMBER ***
date:12-Jun-2009
Example 4 - Intravenous Push with Multiple Syringe and use of TALL man Lettering

Smith, Mary A. 20000298
EPIrubicin 166 mg/83 mL IV
(2 mg/mL)
1 of 2 syringes.
Each syringe contains 83 mg/41.5 mL.
Infuse slowly IV at a rate of 5 mL/minute.

date: 12-Jun-2009

AVOID EXTRAVASATION

Example 5 - Multiple Additives

Smith, John A. 20000133
CaCl₂ 1 g/10 mL IV
(0.1 g/mL)

MgSO₄ 1 g/2 mL IV
(0.5 g/mL)

Solution: D5W Volume: 250 mL
Total volume: 262 mL
Rate: 786 mL/hour
Infuse over 20 minutes prior to oxaliplatin.

date: 12-Jun-2009
FUTURE RESEARCH

More research is needed on the use and effectiveness of strategies to reduce medication administration errors. Specifically, more studies evaluating the effectiveness of bar coding to reduce medication errors and adverse events are needed. In addition, studies are needed to evaluate the best method(s) for patient identification to enhance the safe administration of chemotherapy. There are now a few institutions that generate two labels: one for pharmacy staff who fill the prescriptions and one for the nurses who administer the chemotherapy. Research is needed to determine if a system that makes use of two labels results in fewer medication errors than a system in which one label is used. The safe administration of chemotherapy is a complex process in which good labels are necessary but not a sole or sufficient strategy.

Funding
The PEBC is a provincial initiative of Cancer Care Ontario supported by the Ontario Ministry of Health and Long-Term Care through Cancer Care Ontario. All work produced by the PEBC is editorially independent from its funding source.

Copyright
This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization.

Disclaimer
Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgement in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding the report content or use or application and disclaims any responsibility for its application or use in any way.

Contact Information
For further information about this report, please contact:

**Dr. Maureen Trudeau**, Cancer Care Ontario, 620 University Avenue, Toronto, ON, M5G 2L7
Phone: 416-480-5145  Fax: 416-481-6002  E-mail: Maureen.trudeau@sunnybrook.ca

or

**Esther Green**, Cancer Care Ontario, 620 University Avenue, Toronto, ON, M5G 2L7
Phone: 416-971-9800 x1278  E-mail: esther.green@cancercare.on.ca

For information about the PEBC and the most current version of all reports, please visit the CCO website at [http://www.cancercare.on.ca/](http://www.cancercare.on.ca/) or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822  Fax: 905-526-6775  E-mail: ccopgi@mcmaster.ca
REFERENCES


